Eton Pharmaceuticals Inc. (ETON)

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.

Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to...

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.12 per share a year ago.

Eton Pharmaceuticals (ETON), a biopharmaceutical company focused on rare diseases, posted earnings for Q2 2025 on August 7, 2025. The main highlight was a strong revenue increase from both core and re...

Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA approval for their new drug, Khindivi. Insider sales by the CEO and CBO after Q1 ...

Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attr...

Eton Pharmaceuticals (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it...

The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.'s ETON new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric pat...